Abstract:
A peptic ulcer is damage to the lining of the stomach, duodenum, or esophagus due to
corrosion caused by gastric acid or digestive juices secreted by stomach cells. Among all
classes of drugs, proton pump inhibitors are the most effective for the management of
peptic ulcer diseases. Rabeprazole sodium is one of the prominent proton pump
inhibitors. It is commonly used in the world for the treatment of peptic ulcer. It functions
by inhibiting the enzyme W /K+ ATPase which is responsible for the secretion of gastric
acid. The purpose of this study is to analyze the market feasibility study of Rabeprazole
sodium. Many books, journals and different articles were used to know efficacy and
safety profile of drugs. Rabeprazole sodium blocks acid production in the stomach. It is
prescribed for the short-term (4 to 8 weeks) treatment of sores and inflammation in the
upper digestive canal (esophagus). It is more effective in the treatment of duodenal ulcer,
H. pylori, gastric ulcer, erosive esophagitis, GERD, and pathological hypersecretory conditions, including Zollinger-Ellison syndrome. By the study of market, feasibility
among all PPls Rabeprazole market value is 26,568,572 taka. Rabeprazole market growth
is 2.29%, which is comparatively less among other PPls. To increase overall market
growth I can introduce Rabeprazole sodium, which is a delayed-release tablet. Because
of its D-R property I hope that with in one year it will become a superior drug for the
,treatment of peptic ulcer.
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh.
